SEC Form 4 · accession 0001140361-26-027679
ROCKET PHARMACEUTICALS, INC. · RCKT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mikael Dolsten
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jul 6, 2026 · 7:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001281895
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 18, 2026 | A | 22,862 | $0.00 | A | 67,082 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.35 | Jun 18, 2026 | A | 64,860 | A | — | Jun 18, 2036 | Common Stock | 64,860 | 64,860 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
- F2This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.